Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Have Beyondspring insiders bought shares recently?
No open-market purchase by an insider of Beyondspring is on record in SEC filings since 2006.
How often do Beyondspring insiders buy and sell shares?
Since 2025, Beyondspring insiders reported 0 open-market purchases and 57 sales on Forms 4 and 5.
Who is selling Beyondspring stock?
No open-market sale by an insider of Beyondspring (BYSI) was filed with the SEC in the last 90 days.
Do members of Congress trade BYSI?
No trade in Beyondspring (BYSI) was disclosed by a member of Congress in the last 12 months.
When does Beyondspring report its next results?
Beyondspring's next results are expected on Dec 17, 2026. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
BYSI price and disclosed activity
−81.0% (−$1.41) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.74 on Nov 20, 2025 to $0.33 on Nov 20, 2026 (−81.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
$0.00$1.00$1.50$2.00$2.50$3.00$0.33
DecJan 2026FebMarAprMayJunJulAugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Florham Park, Nj.
Last 12 months
−81.0%
S&P 500 +5.7% over the same dates
Market value
$13.6M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.28M shares sold short (5.5% of shares outstanding), −3.3% vs the previous count, 41.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Red flags in its filings
Oct 2
Notice of delisting or failure to meet listing rules
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insider buying and selling since 2025
Insiders of Beyondspring reported 0 open-market purchases and 57 sales since 2025; no open-market purchase.
Year
Bought
Sold
2025
—
$1.97M57×57 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Since Nov 19, 2025, BYSI is down 83.1% and the index fund is up 4.1%: 87 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much BYSI moves
A usual day
±2.7%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
29.4%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−31.0%Sep 29, 2026
Largest one-day rise
+44.1%Sep 28, 2026
Deepest fall of the year
−86.0%From the close of Dec 19, 2025 to Nov 20, 2026.
Days of 5% or more
69Out of 252 sessions, in either direction.
Beta 1.1(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Beyondspring filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 57 open-market sales (about $1.97M, in 15 filings). (Beyondspring on OQRO)
Contracts, lobbying and filings. FINRA short interest for BYSI on the settlement date of Oct 30, 2026 was 2,276,739 shares (-3.25% on the previous report), about 41.86 days of average volume. In 13F filings for the quarter ended Jun 30, 2025, the largest positions that grew: none on record; the largest that shrank: Banque Transatlantique SA (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Beyondspring filed a Form 8-K on Oct 6, 2026 (Item 2.01) that OQRO classes as: completed buying or selling a business or assets. The company's own opening sentence of that report reads: "On September 30, 2026, BeyondSpring Inc. (the ' Company ') completed the closing (the ' Closing ') of the previously disclosed transactions under the Share Purchase and Collaboration Agreement, dated as of September 28, 2026 (the..."
Who holds it. 22 funds reported a stake in Beyondspring in their 13F for Q2 2026. The largest by value: Decheng Capital LLC (62.7% of the value reported), BlackRock, Inc. (11.1% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (10.3% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Beyondspring filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 57 open-market sales (about $1.97M, in 15 filings).
Contracts, lobbying and filings
FINRA short interest for BYSI on the settlement date of Oct 30, 2026 was 2,276,739 shares (-3.25% on the previous report), about 41.86 days of average volume.
In 13F filings for the quarter ended Jun 30, 2025, the largest positions that grew: none on record; the largest that shrank: Banque Transatlantique SA (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Beyondspring filed a Form 8-K on Oct 6, 2026 (Item 2.01) that OQRO classes as: completed buying or selling a business or assets.
The company's own opening sentence of that report reads: "On September 30, 2026, BeyondSpring Inc. (the ' Company ') completed the closing (the ' Closing ') of the previously disclosed transactions under the Share Purchase and Collaboration Agreement, dated as of September 28, 2026 (the..."
Beyondspring filed a Form 8-K on Oct 2, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange.
Beyondspring filed a Form 8-K on Sep 18, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange.
Press coverage listed by Finnhub: "BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update" (Yahoo, Nov 13, 2026).
Press coverage listed by Finnhub: "BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances" (Yahoo, Sep 29, 2026).
Press coverage listed by Finnhub: "BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update" (Yahoo, Aug 14, 2026).
Latest results: quarter ending Sep 30, 2026
Revenue
$0
Year earlier: $0
Free cash flow, last 12 months
−$16.2M
This quarter −$3.6M, a year earlier −$4.19M
Net debt
—
Debt —, cash $580K, at Sep 30, 2026
Net income, last 12 months
$45.6M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 13, 2026.
BYSI closed at $0.453 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $0.5129 to $0.453, a change of −11.7%.
Who holds it
22 funds reported a stake in Beyondspring in their 13F for Q2 2026. The largest by value: Decheng Capital LLC (62.7% of the value reported), BlackRock, Inc. (11.1% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (10.3% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Latest annual report filed Mar 25, 2026, compared with the one filed Mar 27, 2025. Read the filing
All 86 risk factor headings match the year before, give or take wording.
Legal proceedings (Item 3)
From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Source: SEC EDGAR, Form 10-K filed Mar 25, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
From “Overview”, in the company's words
We are a clinical stage global biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Our first-in-class lead asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate “acquired resistance” from prior ICI treatment in cancer patients. Plinabulin has been administered to over 700 cancer patients with generally good tolerability and is being developed as a potential “pipeline in a drug” in various cancer indications as a direct anti-cancer agent with safety benefit of CIN. We are also developing three small molecule immune agents, which are currently in pre-clinical stages.
What the section covers (23 headings)
Overview
Discontinued Operations
Segments
Components of Results of Operations
Revenue
Operating Expenses
Research and Development Expenses
General and Administrative Expenses
Other Income (Expenses)
Results of Operations
Comparison of Years Ended December 31, 2025 and 2024
Non-Accelerated Filer
Liquidity and Capital Resources
Net Cash Used in Operating Activities
And 9 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 25, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
When insiders usually buy
Last results
Nov 13, 2026
Within the 30 days after it, until Dec 13, 2026
Next results, expected
Dec 17, 2026
Purchases after results
Not enough history
From Beyondspring's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Beyondspring's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Off-exchange trading: 56.1% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (1.8% on ATS, 54.3% with other brokers), below its 26-week average of 64.9%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: IBKR ATS (21.6%), INTELLIGENT CROSS LLC (9.9%), LEVEL ATS (8.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.